Pharmaceutical compositions comprising a polypeptide comprising at least one CXXC motif and heterologous antigens and uses thereof

US9801927B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-9801927-B2
Application numberUS-201113636482-A
CountryUS
Kind codeB2
Filing dateMar 29, 2011
Priority dateMar 29, 2010
Publication dateOct 31, 2017
Grant dateOct 31, 2017

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The invention relates to pharmaceutical compositions using a polypeptide comprising at least one CXXC motif, such as Giardia parasite's variable surface proteins (VSP) or a fragment thereof to raise by oral or mucosal vaccination an immune response against a heterologous selected antigen, such as tumor antigen, microbial antigen or other antigen.

First claim

Opening claim text (preview).

The invention claimed is: 1. An immunogenic composition against an antigen comprising: an antigen bound to a polypeptide, wherein the polypeptide: is heterologous to the antigen, comprises 10 to 14 CXXC motifs, wherein C represents a cysteine residue and X any amino acid residue, is a variable surface protein (VSP), a VSP-like protein of a microorganism or a fragment thereof, and is able to attach to epithelial cells of the gut, and wherein CXXC corresponds to SEQ ID NO 1, wherein the microorganism is selected from the group consisting of Giardia, Tetrahymena, Paramecium and Entamoeba species, wherein the polypeptide is bound to a vector particle containing said antigen, and wherein the vector particle is a viral particle, a viral-like particle (VLP) or a nanoparticle. 2. The immunogenic composition according to claim 1 for use in oral administration. 3. The immunogenic composition according to claim 1 , wherein the polypeptide is resistant to enzymatic and/or chemical degradation of the upper gastrointestinal tract. 4. The immunogenic composition according to claim 1 , wherein the polypeptide is the extracellular domain of VSP or a fragment thereof. 5. The immunogenic composition according to claim 1 , wherein the polypeptide is fused to said antigen. 6. The immunogenic composition according to claim 1 , wherein The polypeptide is bound to a vector particle containing said antigen, and wherein the vector particle is a VLP displaying at its surface the polypeptide. 7. The immunogenic composition according to claim 6 , wherein the antigen is contained inside or on the surface of the VLP. 8. The immunogenic composition according to claim 1 , wherein the vector particle is a nanoparticle displaying at its surface the polypeptide and the heterologous antigen. 9. A pharmaceutical composition comprising at least the vaccine according to claim 1 . 10. A method of immunization of a subject against an influenza A H5N1, wherein said method comprises administering to said subject said antigen bound to a polypeptide, wherein the polypeptide: is heterologous to said antigen, comprises 10 to 14 CXXC motifs, wherein C represents a cysteine residue and X any amino acid residue, is a variable surface protein (VSP), a VSP-like protein of a microorganism or a fragment thereof, and is able to attach to epithelial cells of the gut, and wherein CXXC corresponds to SEQ ID NO 1, wherein the microorganism is selected from the group consisting of Giardia, Tetrahymena, Paramecium and Entamoeba species, wherein the polypeptide is bound to a vector particle containing said antigen, and wherein the vector particle is a viral particle, a viral-like particle (VLP) or a nanoparticle. 11. The method of claim 10 , wherein said antigen bound to a polypeptide is administered by oral route.

Assignees

Inventors

Classifications

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US9801927B2 cover?
The invention relates to pharmaceutical compositions using a polypeptide comprising at least one CXXC motif, such as Giardia parasite's variable surface proteins (VSP) or a fragment thereof to raise by oral or mucosal vaccination an immune response against a heterologous selected antigen, such as tumor antigen, microbial antigen or other antigen.
Who is the assignee on this patent?
Klatzmann David, Piaggio Eliane, Luján Hugo Daniel, and 5 more
What technology area does this patent fall under?
Primary CPC classification A61K39/145. Mapped technology areas include Human Necessities.
When was this patent published?
Publication date Tue Oct 31 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).